Multi-functional activities of citrus flavonoid NARIRUTIN (cas 14259-46-2) in Alzheimer’s disease therapeutics: An integrated screening approach and in vitro validation

Add time:07/17/2019    Source:sciencedirect.com

Alzheimer’s disease (AD) is a complex disorder and the disease mechanism is yet to be properly characterized. Over the years, “amyloid cascade” emerges as principal pathogenic event in AD. β-Secretase 1 (BACE1) controls the rate-limiting step in amyloid beta (Aβ) generation and Aβ rapidly aggregates to form neurotoxic amyloid fibrils. Oxidative stress is one of the principal mediators of the observed neurotoxicity of amyloid fibril. The disease pathogenesis involves induction of multiple signaling cascades and the cross-talk therein. Thus inhibiting multiple targets could be an attractive therapeutic strategy. Here, a multi-target virtual screening protocol has been devised and used to screen an in house developed phytochemical library. NARIRUTIN (cas 14259-46-2) comes out as a multi-potent phytochemical. Steady-state and time-resolved fluorescence along with molecular modelling studies demonstrate its binding to the BACE1 active site that induces a conformational transition of the protein from open to closed form which precludes substrate recognition. Narirutin possesses strong Aβ aggregation inhibitory potential, evident from ANS and Thioflavin-T binding assay and confirmed by AFM study. ABTS·+ scavenging assay shows moderate antioxidant activity for narirutin. The applicability of a multi-target screening strategy in AD therapeutics is thus demonstrated and the identified hit, narirutin, shows strong multi-potent activity.

We also recommend Trading Suppliers and Manufacturers of NARIRUTIN (cas 14259-46-2). Pls Click Website Link as below: cas 14259-46-2 suppliers

Prev:Attenuation of isoproterenol-induced cardiotoxicity in rats by NARIRUTIN (cas 14259-46-2) rich fraction from grape fruit
Next:NARIRUTIN (cas 14259-46-2) fraction from citrus peels attenuates LPS-stimulated inflammatory response through inhibition of NF-κB and MAPKs activation)